| 生物活性 |
Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor (Dopamine Receptor) agonist and CaV1.3 calcium channel modulator that restores dendritic spine density in dopamine-depleted striatum, upregulates BCL2 and GluR2 protein expression, downregulates BAX protein expression, and delays seizure onset; it enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and can induce anxiety-like, stereotyped, and compulsive behaviors; furthermore, Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances paraventricular thalamic nucleus neuronal activity to promote emergence from Isoflurane anesthesia, and alters gut microbiota composition in rats, and it can be used for research on dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorders, obsessive-compulsive disorder, and schizophrenia. |
体内研究 (In Vivo) |
Quinpirole (0.05-0.1 mg/kg;皮下注射;每日 2 次;持续 4 周) 可持续且显著地抑制 Levodopa (MS-R94530) 诱导的异动症,并预防帕金森病大鼠多巴胺耗竭纹状体中异常蘑菇状树突棘的形成。 Quinpirole (0.1-3 mg/kg;皮下注射) 在未处理雄性 Wistar 大鼠、完全弗氏佐剂 (CFA) 诱导炎性疼痛模型、CCI 诱导的神经性疼痛中的机械伤害感受试验中可产生显著的镇痛作用,产生显著的伤害感受增强作用。 Quinpirole (侧脑室注射;单剂量;Pilocarpine 注射前 60 分钟) 对Lithium chloride (MS-D56483)-Pilocarpine (MS-U99376) 诱导的癫痫 Wistar 大鼠具有神经保护作用,可延迟癫痫发作起始、改善认知功能,并调控海马组织中 GluR2、BAX 及 BCL2 的蛋白表达。 Quinpirole (0.01-3 mg/kg,腹腔注射,处死前 1-4 小时) 可呈剂量依赖性降低大鼠下丘脑肾上腺素及大脑半球多巴胺代谢物的浓度;高剂量时还会改变下丘脑多巴胺、去甲肾上腺素以及脑干 MHPG 硫酸盐的浓度。 Quinpirole (5.5-50 μM; immersion; single 24-hour exposure; at 5 dpf) 可诱导成年斑马鱼出现持续性焦虑样行为、刻板游动及厌恶记忆损伤,而对其社交或攻击行为无影响。 Quinpirole (7-70 nM;向伏隔核核心双侧脑内输注;0.2 μl/min) 会破坏听觉惊跳反射的前脉冲抑制。 Quinpirole (0.5 mg/kg,皮下注射,每周 2 次,持续 5 周) 可在成年雄性 Wistar 大鼠中诱导类强迫症行为、神经炎症改变、肠道组织学变化、粪便短链脂肪酸水平降低及肠道菌群失调。 Quinpirole (4 mM,经丘脑室旁核微注射,总容积 0.5 μl,给药时长 2 分钟) 可显著缩短雄性 C57BL/6J 小鼠从 Isoflurane (MS-I85200) 麻醉中的苏醒时间、降低皮层爆发抑制比,并增强丘脑室旁核神经元活性。
| Animal Model: |
Sprague-Dawley (adult male, 250g, unilateral stereotaxic injection of 6-hydroxydopamine hydrobromide to induce Parkinson's disease) |
| Dosage: |
0.1 mg/kg (first 12 days); 0.05 mg/kg (remainder of experiment) |
| Administration: |
s.c.; twice daily; 4 weeks |
| Result: |
Suppressed total levodopa-induced dyskinesia (LID) severity significantly compared to vehicle controls on day 5 and day 10 of levodopa treatment. Reduced peak LID severity significantly compared to vehicle controls on day 10. Dampened LID severity significantly compared to vehicle controls at the 70-minute post-levodopa peak of LID expression on day 10. Showed no significant difference in total spine density and thin spine density between dopamine-depleted and intact striatum, unlike vehicle-treated rats. Prevented the significant increase in mushroom spine density in the dopamine-depleted striatum observed in vehicle-treated dyskinetic rats. |
| Animal Model: |
Wistar (male, 220-350 g) |
| Dosage: |
0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg |
| Administration: |
s.c. |
| Result: |
Showed no significant changes in thermonociceptive withdrawal latencies or AUC compared to saline. Significantly increased mechanonociceptive withdrawal latencies at 30 min and 1 h at 1 mg/kg dose. Significantly increased mechanonociceptive withdrawal latencies at 30 min and 1 h at 3 mg/kg dose. Produced significant AUC increases in mechanonociceptive tests at 1 mg/kg and 3 mg/kg doses. Had its antinociceptive effect at 1 mg/kg completely prevented by co-administration with 0.3 mg/kg raclopride. |
| Animal Model: |
Wistar (Hsd: [WI]BR) (male, 150-200 g) |
| Dosage: |
0.01 mg/kg; 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg |
| Administration: |
i.p.; 1 hour prior to sacrifice (1 mg/kg); 2 hours prior to sacrifice (2, 3 mg/kg); 4 hours prior to sacrifice (0.01, 0.03, 0.1, 0.3, 1, 3 mg/kg) |
| Result: |
Reduced cerebral hemisphere homovanillic acid (HVA) concentration by 13% at 0.03 mg/kg. Reduced cerebral hemisphere 3,4-dihydroxyphenylacetic acid (DOPAC) concentration by 22% and HVA by 29% at 0.1 mg/kg. Reduced hypothalamic epinephrine concentration by 41%, cerebral hemisphere DOPAC by 32%, and HVA by 43% at 0.3 mg/kg; left hypothalamic dopamine and norepinephrine concentrations unchanged. Reduced hypothalamic epinephrine concentration by 53%, cerebral hemisphere DOPAC by 41%, and HVA by 52% at 1 mg/kg; left hypothalamic dopamine and norepinephrine concentrations unchanged. In a separate experiment, reduced hypothalamic epinephrine by 23%, cerebral hemisphere DOPAC by 36%, and HVA by 48% at 1 mg/kg; these effects were blocked by spiperone pretreatment. Reduced hypothalamic epinephrine concentration by 35%, hypothalamic norepinephrine by 12%, and increased hypothalamic MHPG sulfate by 85% at 2 mg/kg. Reduced hypothalamic epinephrine concentration by 41%, cerebral hemisphere DOPAC by 26%, and HVA by 45% at 3 mg/kg; these effects were blocked by spiperone pretreatment. In another experiment, increased hypothalamic dopamine concentration by 21%, reduced hypothalamic norepinephrine by 16%, and increased brain stem MHPG sulfate by 26% at 3 mg/kg; all these effects were blocked by spiperone pretreatment. In a third experiment, reduced hypothalamic epinephrine by 40%, increased hypothalamic dopamine by 17%, reduced hypothalamic norepinephrine by 8%, and increased brain stem MHPG sulfate by 65% at 3 mg/kg. |
| Animal Model: |
wild-type AB strain (both genders) |
| Dosage: |
5.5 μM; 16.7 μM; 50 μM |
| Administration: |
immersion; single 24-hour exposure; at 5 dpf |
| Result: |
Increased time spent at the tank bottom in open tank test for 50 μM dose, indicating anxiety-like behavior. Increased absolute turn angle in open tank test for 16.7 μM dose, indicating elevated erratic movements. Increased duration and frequency of stereotypic swimming in open tank test across all doses. Decreased test session latency compared to controls in inhibitory avoidance task. Caused no significant changes in distance traveled, time mobile, or acceleration across all doses. Caused no significant differences in social interaction task metrics compared to controls. Caused no significant differences in aggression test metrics compared to controls. |
| Animal Model: |
Macaca mulatta (male, 4-7 years old, 6-12 kg) |
| Dosage: |
7 nmol; 35 nmol; 70 nmol |
| Administration: |
bilateral intracerebral infusion into nucleus accumbens core; 0.2 μl/min |
| Result: |
Reduced baseline startle amplitude on pulse-alone trial. Disrupted PPI significantly when collapsed across all doses compared to vehicle/sham. Disrupted PPI significantly when collapsed across 35 nM and 70 nM doses compared to vehicle/sham, with significant deficits at 8 dB and 12 dB prepulse intensities. Reduced PPI significantly at 12 dB prepulse intensity alone at 70 nM dose compared to vehicle/sham. |
| Animal Model: |
Wistar rats (adult male, 240 g; obsessive-compulsive disorder model via subcutaneous quinpirole injections twice weekly for 5 weeks) |
| Dosage: |
0.5 mg/kg |
| Administration: |
s.c.; twice weekly; 5 weeks |
| Result: |
Increased marble burying. Increased self-grooming activity. Decreased time spent in open arms and decreased open arm entries in the elevated plus maze. Showed non-significant decrease in head dipping activity in the hole board test. Increased mRNA expression of interleukin-6 and C-reactive protein in the amygdala, with statistically insignificant increase in tumor-necrosis factor-α. Increased neuronal nitric oxide synthase levels in the frontal cortex. Showed non-significant changes in frontal cortex dopamine, noradrenaline, and 5-hydroxytryptamine levels. Reduced goblet cell count and villus height/crypt depth ratio in the colon. Decreased fecal levels of acetate, propionate, and butyrate. Altered gut microbiota composition including increased relative abundance of Allobaculum, Bifidobacterium (specifically Bifidobacterium animalis), and decreased relative abundance of Lactobacillus (including Lactobacillus reuteri and Lactobacillus vaginalis) at the genus and species levels. |
| Animal Model: |
C57BL/6J (male, 25-30 g) |
| Dosage: |
2 mM; 4 mM |
| Administration: |
intra-PVT microinjection; 0.5 μl total volume over 2 minutes |
| Result: |
Shortened emergence time to 182.1 s (4 mM dose) compared to saline control. Showed no significant effect on emergence time at 2 mM dose (261.3 s) relative to saline. Did not alter isoflurane induction time at either 2 mM or 4 mM dose relative to saline. Decreased burst suppression ratio from 42.78% pre-injection to 35.15% post-injection. Increased mean number of c-Fos-positive nuclei in the PVT to 371.2 per mm2 (4 mM dose) compared to saline control. |
|